Combined treatment with MNK1/2 inhibitors and anti-PD-1/PD-L1 demonstrated its efficacy in several mouse melanoma models, arguing in favor of defining a new strategy to inhibit melanoma plasticity and improve response to anti-PD-1 immunotherapy. Here, MKNK1 is linked to melanoma.